aTyr Pharma (LIFE) Issues Encouraging Update on Resolaris Phase 1b/2 in Adult FSHD; Data Supports Advancement
Tweet Send to a Friend
aTyr Pharma, Inc. (Nasdaq: LIFE) announced results from a Phase 1b/2 clinical trial evaluating Resolaris™ in adult FSHD (facioscapulohumeral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
